The present disclosure relates generally to systems and methods for treating pulmonary edema.
The lymphatic system is part of the circulatory system in conjunction with the arterial and venous systems. A primary function of the lymphatic system is to drain excessive interstitial fluid back into the venous system at two main locations: the thoracic duct and the lymphatic duct, which drain into the left and right subclavian veins, respectively.
Under normal circulatory conditions of the arterial and venous systems the interstitial fluid volume balance is maintained and the lymph fluid is cleared back through the lymphatic system. In pathological conditions such as Acute Cardiogenic Pulmonary Edema and chronic heart failure, the capillary hydrostatic pressure and the venous pulmonary pressure can become elevated and fluid flows excessively out of the blood vessels and into the interstitial and alveolar spaces. The pressure gradient between the initial lymphatics and at the outflow of the thoracic duct and the lymphatic duct is reduced and the lymphatic system cannot clear the additional fluid which accumulates in the air spaces of the lungs. This is a life threatening condition as gas exchange is impaired to the extent that it may lead to respiratory failure.
Current treatment methods require extended hospitalization and treatment with loop diuretics and/or vasodilators. Oftentimes patients must also receive supplemental oxygen or, in more extreme cases, require mechanical ventilation. Many of these treatment methods are less than ideal because the edema is not always alleviated rapidly enough and for many patients renal function is adversely affected. A significant percentage of patients do not respond to this treatment and a significant percentage must be readmitted to a hospital within 30 days.
A significant problem with current treatment protocol is that it is based on the need to reduce intravascular blood pressure to move lymphatic fluid back into the vasculature. The reduction of intravascular blood pressure leads to leads to hypotension and activates the Renin Angiotenesin Aldesterone System, which leads to an increase in blood pressure. Eventually, this cycle leads to diuretic resistance and the worsening of renal function in almost 30% of admitted patients.
Accordingly, there remains a need for improved methods and devices for systems and methods for treating pulmonary edema.
Various systems and methods are provided for treating pulmonary edema. In one embodiment a system for treatment of edema includes a pump configured to be implanted in a body of a patient, an inflow tube fluidically coupled to an inflow port of the pump and configured to be implanted into the body of the patient so as to bring the inflow port into fluid communication with a lymphatic vessel of the patient, and an outflow tube fluidically coupled to an outflow port of the pump and configured to be implanted into the body of the patient so as to bring the outflow port into fluid communication with a vein in the body of the patient such that the pump is operative to pump fluid from the lymphatic vessel to the vein.
The system can vary in any number of ways. For example, the system can include a controller configured to actuate the pump. The controller can be configured to actuate the pump in response to user operation of a control external to the body of the patient, and/or the system can include a pressure sensor configured to be implanted in the body of the patient. The controller can be configured to actuate the pump in response to a pressure measured by the pressure sensor exceeding a predefined threshold, and/or the controller can be configured to control a speed of operation of the pump depending on a pressure measured by the pressure sensor.
For another example, the pump can be configured to continuously pump the fluid from the lymphatic vessel to the vein.
For yet another example, the system can include a power source configured to be implanted in the body of the patient and configured to provide power to the pump.
For another example, the system can include a charging coil configured to inductively couple to a power source external to the body of the patient and thereby provide power to the pump.
For yet another example, the pump can be configured to pump fluid at a rate in a range of about 10 to 1000 ml/hour, e.g., in a range of about 10 to 200 ml/hour.
In another aspect, a method is provided that in one embodiment includes implanting a pump in a body of a patient, the pump being operable to convey a bodily fluid from an inflow port of the pump to an outflow port of the pump, arranging a first tube in fluid communication with the inflow port to be in fluid communication with a lymphatic vessel of the patient, and arranging a second tube in fluid communication with the outflow port to be in fluid communication with a vein of the patient such that the pump is operable to convey fluid from the lymphatic vessel to the vein.
The method can have any number of variations. For example, the method can include actuating the pump, thereby causing the pump to convey the fluid, e.g., lymph, from the lymphatic vessel to the vein of the patient. The actuated pump can maintain an outflow pressure in a range of about 2 to 6 mmHg, the pump can be actuated in response to user operation of a control external to the body of the patient, and/or the pump can be configured to be actuated periodically or continuously.
For another example, the lymphatic vessel can include one of a thoracic duct of the patient and a lymphatic duct of the patient.
For yet another example, the vein can include one of the patient's subclavian vein, internal jugular vein, innominate vein, and superior vena cava.
For still another example, the method can include implanting a pressure sensor in a location within the body of the patient that enables the pressure sensor to measure pressure in a desired region of the body of the patient. The method can include measuring the pressure in the desired region using the pressure sensor, and actuating the pump in response to the measured pressure exceeding a predefined threshold and/or controlling a speed of operation of the pump depending on the measured pressure.
For another example, the pump can be implanted adjacent to one of a junction of the patient's left subclavian vein and internal jugular vein and a junction of the patient's right subclavian vein and internal jugular vein.
For yet another example, the pump can include a power source, and the method can include recharging the power source by inductive coupling to a power source external to the body of the patient.
For another example, the pump can include a power source, and the method can include recharging the power source by inductive coupling to a power source external to the body of the patient.
For still another example, the method can include advancing a wire into the body of the patient and into the lymphatic vessel, verifying the position of the wire within the lymphatic vessel, and then arranging the first tube.
This invention will be more fully understood from the following detailed description taken in conjunction with the accompanying drawings, in which:
Certain exemplary embodiments will now be described to provide an overall understanding of the principles of the structure, function, manufacture, and use of the devices and methods disclosed herein. One or more examples of these embodiments are illustrated in the accompanying drawings. Those skilled in the art will understand that the devices and methods specifically described herein and illustrated in the accompanying drawings are non-limiting exemplary embodiments and that the scope of the present invention is defined solely by the claims. The features illustrated or described in connection with one exemplary embodiment may be combined with the features of other embodiments. Such modifications and variations are intended to be included within the scope of the present invention.
Reference throughout the specification to “various embodiments,” “some embodiments,” “one embodiment,” or “an embodiment,” or the like, means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, appearances of the phrases “in various embodiments,” “in some embodiments,” “in one embodiment,” or “in an embodiment,” or the like, in places throughout the specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. Thus, the particular features, structures, or characteristics illustrated or described in connection with one embodiment may be combined, in whole or in part, with the features structures, or characteristics of one or more other embodiments without limitation.
It will be appreciated that the terms “proximal” and “distal” may be used throughout the specification with reference to a clinician manipulating one end of an instrument used to treat a patient. The term “proximal” refers to the portion of the instrument closest to the clinician and the term “distal” refers to the portion located furthest from the clinician. It will be further appreciated that for conciseness and clarity, spatial terms such as “vertical,” “horizontal,” “up,” and “down” may be used herein with respect to the illustrated embodiments. However, surgical instruments may be used in many orientations and positions, and these terms are not intended to be limiting and absolute.
Further, in the present disclosure, like-named components of the embodiments generally have similar features, and thus within a particular embodiment each feature of each like-named component is not necessarily fully elaborated upon. Additionally, to the extent that linear or circular dimensions are used in the description of the disclosed systems, devices, and methods, such dimensions are not intended to limit the types of shapes that can be used in conjunction with such systems, devices, and methods. A person skilled in the art will recognize that an equivalent to such linear and circular dimensions can easily be determined for any geometric shape. Sizes and shapes of the systems and devices, and the components thereof, can depend at least on the anatomy of the subject in which the systems and devices will be used, the size and shape of components with which the systems and devices will be used, and the methods and procedures in which the systems and devices will be used.
Various systems and methods are provided for treating pulmonary edema. In general, a pump can be configured to be implanted within a patient at risk of developing edema. The pump can be configured to pump fluid out of the patient's lungs, e.g., out of the patient's interstitial and alveolar spaces, which can help prevent the fluid from building up to a dangerous degree. The pump can thus be configured to facilitate prevention of edema by limiting fluid build-up in the lungs, if not preventing fluid build-up entirely. In other words, the pump can be configured to facilitate treatment of chronic edema, such as can occur in connection with chronic heart failure. The pump can be configured to facilitate higher lymphatic return by lowering outflow pressure at a lymphatic vessel of the patient, e.g., at the patient's thoracic duct and/or lymphatic duct. The pump can be configured to be fully implanted within the patient's body, thereby helping the device to be unobtrusive in the patient's daily life, similar to a pacemaker. The pump can be configured to continuously pump fluid, which can help ensure the removal of fluid that collects in the lung space before a dangerous amount of the fluid builds up and/or can help ensure the long term patency of the pump. In other words, the pump can be configured to continuously run and provide fluid flow. Alternatively, the pump can be configured to be selectively actuatable in response to a trigger event, such as in response to a value of a measured parameter (e.g., pressure, fluid amount, bioimpedance, heart rate, breathing rate, patient activity level, organ dimension, etc.) or in response to a user input requesting pumping. The pump can thus be configured to only periodically pump fluid, e.g., only periodically run so as to alternate between periods in which the pump is running to provide fluid flow and in which the pump is not running. Running periodically can help conserve power (e.g., battery power, electrical power, etc.) and/or can be appropriate for patients with lower risks of developing edema and/or for patients who tend to be more at risk of developing edema at certain times (e.g., during the day instead of at night, when exercising, etc.) instead of having a more constant risk. In at least some embodiments, the pump can be configured to be selectively switched between a continuous mode in which the pump runs continuously and a periodic mode in which the pump runs periodically, which can help the pump be most effectively used according to each patient's current needs.
In an exemplary embodiment, in use, the pump can include an inflow port coupled to an inflow tube in fluid communication with a lymphatic vessel of the patient, and can include an outflow port coupled to an outflow tube in fluid communication with a vein of the patient (e.g., the patient's subclavian vein, internal jugular vein, innominate vein (also referred to as a “brachiocephalic vein”), or superior vena cava). The pump can thus be configured to pump fluid from the lymphatic vessel to the vein so as to facilitate removal of fluid from the lymphatic vessel and thereby facilitate higher lymphatic return by lowering outflow pressure at the lymphatic vessel. Because lymphatic systems can have different anatomies in different patients, the inflow tube can be positioned to be in fluid communication with the patient's lymphatic duct, the patient's thoracic duct, or any duct that drains into the patient's subclavian vein, jugular vein, innominate vein, or superior vena cava.
The pump 10 can have a size configured to facilitate implantation of the pump 10 within the patient's lung. In at least some embodiments, the pump 10 can have a size configured to allow the pump 10 to be implanted within a vein of the patient. In at least some embodiments, the pump 10 can have a size too large to be implanted with the patient's vein and small enough to be implanted within a duct of the patient, e.g., a thoracic duct of the patient or a lymphatic duct of the patient. In an exemplary embodiment, the pump 10 can have a length in a range of about 2 to 3 cm and a diameter of about 20 mm.
The pump 10 can be configured to pump fluid at a rate that facilitates draining of fluid (e.g., lymph) from the patient's lymphatic vessel. In an exemplary embodiment, the pump 10 can be configured to pump fluid at a rate in a range of about 10 to 1000 ml/hour, e.g., in a range or about 10 to 200 ml/hour, about 10 ml/hour, about 60 ml/hour, up to about 200 ml/hour, etc. In at least some embodiments, the pump 10 can have a static, e.g., unchangeable, flow rate. The flow rate can thus be predictable and/or chosen for a specific patient. In other embodiments, the pump 10 can have an adjustable flow rate. The flow rate being adjustable can help the pump 10 accommodate changes in the patient's condition over time. The flow rate can be adjustable in a variety of ways, as will be appreciated by a person skilled in the art, such as by being wirelessly adjusted using a user-operated control device located external to the patient and configured to wirelessly communicate with the pump 10 to adjust the flow rate thereof.
The pump 10 can include an inflow port configured to be coupled to an inflow tube (not shown), and can include an outflow port configured to be coupled to an outflow tube (not shown). The inflow and outflow tubes can each be removably coupled to their respective ports of the pump 10 or can each be permanently coupled to their respective ports. The inflow and outflow tubes can each be flexible to facilitate their positioning within tortuous and/or curved lumens in the patient's body. The inflow and flexible tubes can each include, e.g., indwelling catheters. In an exemplary embodiment, both of the inflow and outflow tubes are coupled to the pump 10 in a same manner, e.g., both removable or both permanent. As will be appreciated by a person skilled in the art, fluid can be configured to flow in to the pump 10 through the inflow port and out of the pump 10 through the outflow port, thereby facilitating pumping of the fluid.
The pump 10 can be powered in a variety of ways. In at least some embodiments, the pump 10 can be configured to be powered by an implantable power source. In this illustrated embodiment, the pump 10 is coupled to a power lead 12, also shown in
Instead of the power source 14 being implanted, in at least some embodiments, the pump 10 can be configured to be powered by a power source located external to the patient. The externally-located power source can allow for a more powerful and/or larger power source than implanted power sources, and/or can help reduce an amount of material implanted into the patient, which can help reduce chances of complications. The pump 10 can be configured to wirelessly communicate with the externally-located power source to receive power therefrom. In at least some embodiments, the pump 10 can include a charging coil configured to inductively couple to the externally-located power source so as to receive power therefrom. In at least some embodiments, a handheld device can include the externally-located power source and can configured to be moved in proximity of the pump 10 to wirelessly communicate therewith. In at least some embodiments, the externally-located power source can be included as part of a wearable element that the patient can wear, e.g., on a belt, on a necklace, etc., to keep the power source in effective range of the pump 10.
The pump 10 can be configured to continuously pump fluid, e.g., continuously pump fluid through the inflow port and out the outflow port. The pump 10 can thus be configured to continuously pump fluid out of the area at which an input opening of the inflow tube coupled to the inflow port is located, e.g., out of a lymphatic vessel of the patient such as the patient's thoracic duct or lymphatic duct, and into the area at which an output opening of the outflow tube coupled to the inflow port is located, e.g., into a vein of the patient such as the patient's subclavian vein, internal jugular vein, innominate vein, or superior vena cava.
The pump 10 can be configured to periodically pump fluid, e.g., have alternating periods of pumping and no pumping. The pump 10 can be configured to periodically pump on a set schedule, e.g., alternately pump for “X” minutes and not pump for “Y” minutes, where “X” and “Y” can be equal or different. The set schedule can be preprogrammed into the pump 10, e.g., in a controller thereof (discussed further below). The set schedule can be static or can be adjustable. The set schedule can be adjustable in a variety of ways, as will be appreciated by a person skilled in the art, such as by being wirelessly adjusted using a user-operated control device located external to the patient and configured to wirelessly communicate with the pump 10 to adjust the pumping schedule thereof. Having a set schedule can allow the pump 10 to be relatively simple electronically and not require much processing capability.
Instead of having a set pumping schedule, the pump 10 can be configured to not pump (e.g., be in an idle state) until the occurrence of a trigger event. In other words, the pump 10 can have a default idle state and can be configured to move between the default idle state and an active state in which the pump 10 pumps fluid in response to the trigger event. The trigger event can be manually controlled (e.g., user-controlled) or can be dynamically controlled (e.g., non-user-controlled). A manually controlled trigger event can include a user input to the pump 10 requesting pumping. The pump 10 can thus be configured for on-demand pumping. The user can therefore cause pumping when desired (e.g., during a shortness of breath episode, when the user notices a slight weight gain, etc.) which can help the pump 10 run efficiently and when most needed as determined by the user. The user can include the patient or another person, such as the patient's doctor, the patient's caretaker, etc. The input can be provided to the pump 10 in a variety of ways. In an exemplary embodiment, the input can be provided wirelessly to the pump 10 using a user-operated control device located external to the patient and configured to wirelessly communicate with the pump 10 to cause the pump 10 to start pumping (e.g., change the pump 10 from the idle state to the active state) or to stop pumping (e.g., change the pump 10 from the active state to the idle state).
In addition or in alternative to the pump 10 being configured to pump/not pump in response to a manual trigger event, the pump 10 can be configured to dynamically switch between pumping and not pumping in response to a dynamic trigger event. A dynamic trigger event can include a value of a measured parameter being out of range as compared to a threshold value and/or threshold range of values. The parameter can be measured using a sensor (not shown) associated with the patient having the pump 10 implanted therein. Examples of sensors that can be used to measure a parameter include pressure sensors (e.g., central venous pressure (CVP) or other fluid pressure sensors, and blood pressure sensors), radio frequency transmitters and receivers, fluid sensors, bioimpedance sensors, heart rate sensors, breathing sensors, activity sensors, optical sensors. Pressure sensors can be placed, for example, in the patient's venous system, in the patient's heart, in the patient's arterial system, and/or in the patient's body at target anatomical sites that may suffer from an increase of interstitial fluid overload. Fluid sensors can be placed, for example, in the lungs. Examples of the measured parameter include pressure (e.g., as measured by a pressure sensor), fluid amount (e.g., as measured by a fluid sensor), bioimpedance (e.g., as measured by a bioimpedance sensor), heart rate (e.g., as measured by a heart rate sensor), breathing rate (e.g., as measured by a breathing sensor), patient activity level (e.g., as measured by an activity sensor), and organ dimension (e.g., as measured by an optical sensor). The sensor can be implanted in the patient as part of the pump 10, implanted in the patient as a separate component from the pump 10 (e.g., implanted in an interstitial space around the lung, implanted at a junction of 20 of a right subclavian vein 22 of the patient and an internal jugular vein 24 of the patient, implanted at a junction (not shown) of a left subclavian vein (not shown) of the patient and the internal jugular vein 24, etc.), or the sensor can be located external to the patient, such as by being on a skin surface thereof. If not already a part of the pump 10 so as to be in electronic communication therewith, the sensor can be configured to be in electronic communication with the pump 10 over a communication line such as a wired line or a wireless line. The sensor can include one or more sensors. In embodiments including a plurality of sensors, each of the sensors can be configured to measure the same parameter as or a different parameter than any one or more of the other sensors.
In at least some embodiments, the pump 10 can be configured to change its pumping rate (e.g., from zero to a non-zero value, from a non-zero value to zero, or from one non-zero value to another non-zero value) based on pressure measured by a pressure sensor. If the measured pressure exceeds a predetermined threshold maximum pressure value, the pump 10 can be configured to increase its pump rate (e.g., increase from zero or increase from some non-zero value) in an effort to decrease the pressure.
In at least some embodiments, the pump 10 can be configured to change its pumping rate (e.g., from zero to a non-zero value, from a non-zero value to zero, or from one non-zero value to another non-zero value) based on a fluid amount measured by a fluid sensor. If the measured fluid amount exceeds a predetermined threshold maximum fluid amount value, the pump 10 can be configured to increase its pump rate (e.g., increase from zero or increase from some non-zero value) in an effort to decrease the amount of fluid present.
In at least some embodiments, a fluid sack 11 can be implanted within the patient to facilitate continuous pumping of the pump 10. The fluid in the sack can be in fluid communication with the inflow and outflow ports of the pump 10. The fluid in the sack can include a biocompatible fluid such as saline and can include a coagulation medication. The biocompatible fluid can generally serve as a carrier for the coagulation medication. The coagulation medication can facilitate long term patency of the pump 10 by allowing circulation through the system when more robust pumping by the pump 10 is not required. The pump 10 can thus be configured to continuously pump at different rates, with the different rates being changed in response to trigger events such as those discussed above with respect to periodic pumping.
The pump 10 can include only a continuous mode of operation such that the pump 10 can only continuously pump fluid, the pump 10 can include only a periodic mode of operation such that the pump 10 can only periodically pump fluid, or the pump 10 can include the continuous and periodic modes of operation and be configured to be selectively switched between the continuous mode of operation and the periodic mode of operation. The mode switching can be accomplished in a variety of ways, as will be appreciated by a person skilled in the art such as by being wirelessly switched using a user-operated control device located external to the patient and configured to wirelessly communicate with the pump 10 to change the mode of operation thereof.
A controller (e.g., a processor, a microcontroller, etc.) in electronic communication with the pump 10 can be configured to facilitate control of the pump 10, e.g., control changing the pump's mode of operation, etc. The controller can be included as part of the pump 10 so as to be configured to be implanted in the patient with the pump 10, or, as in this illustrated embodiment, the controller can be a separate component from the pump 10. The controller being part of the pump 10 can help allow the pump 10 to be a self-contained system, although in such a controller requires space in the pump 10, which can increase a size of the pump 10. The controller being a separate component from the pump 10 can help the pump 10 have a smaller size and/or can allow the pump 10 to be controlled by a more powerful processor since the processor can be more easily upgraded than if implanted with the pump 10 and/or since the processor's size can be less important when outside the pump 10 as opposed to inside the pump 10.
Referring again to the embodiment of
In an exemplary embodiment, the pump 10 can be implanted adjacent the junction 20 of the right subclavian vein 22 of the patient and the internal jugular vein 24 of the patient (as in this illustrated embodiment) or adjacent the junction (not shown) of the left subclavian vein of the patient and the internal jugular vein 24. The junction 20 of the right subclavian vein 22 and the internal jugular vein 24 and the junction of the left subclavian vein and the internal jugular vein 24 are where the patient's thoracic and lymphatic ducts drain. For patients at risk of developing edema, outflow pressure at the junction 20 of the right subclavian vein 22 and the internal jugular vein 24 and at the junction of the left subclavian vein and the internal jugular vein 24 are typically highly elevated, e.g., to values greater than about 10 mmHg, over normal outflow pressure, e.g., about 5 mmHg. Pressures in excess of about 25 mmHg can completely stop lymphatic return, and during chronic elevations of pressure, lymphatic flow can be much greater than 25 mmHg. Providing the pump 10 adjacent one of these junctions can thus help regulate fluid thereat, thereby helping to prevent edema from occurring. The pump 10 can be configured to regulate the pressure at the junction to which it is adjacent to a safe, non-edemic level such as its normal level, e.g., about 5 mmHg, or within a range of about 2 to 6 mmHg. With the pump 10 located in the left or right lymphatic duct adjacent one of the junctions, the pressure regulation can be performed from within the body's natural fluid flow system, thereby allowing the pump 10 to pump at a relatively low flow rate to achieve the normal pressure level, e.g., a flow rate in a range or about 10 to 200 ml/hour, about 10 ml/hour, about 60 ml/hour, up to about 200 ml/hour, etc. This relatively low flow rate corresponds to a relatively low pressure increase on the fluid discharged into the patient's venous circulation from the outflow tube in fluid communication with the pump's output port. The pressure gradient that that pump 10 discharges against is less than about 15 mmHg. This relatively low flow rate and this pressure gradient can allow the pump 10 to function with a very low energy consumption (e.g., with a low drain on the power source 14), can allow for a very small power source (e.g., a very small battery such as those used with pacemakers and implantable cardioverter-defibrillators (ICDs)), and/or can allow for the pump 10 to be very small and thereby facilitate implantation thereof.
The embodiment of
As illustrated, the pump 600 can include an impeller, which is a type of rotor pump. In an exemplary embodiment, the pump 600 can have a diameter in a range of about 1 to 5 mm, which can facilitate its implantation within a small body space as discussed above, and can be configured to pump fluid at a rate in a range of about 10 to 100 ml/min. The pump 600 can include therein a power source (not shown) such as a battery, a controller (not shown) such as a microprocessor or other miniature control electrical board, and a motor 618 configured to drive the pump 600. The pump 600 can be configured to be activated manually for on-demand pumping and/or to be activated automatically in response to a dynamic trigger, as discussed above.
The pump 600 can be used in a variety of methods for treating pulmonary edema, as discussed further below. In general, the pump 600 can be implanted in the patient via a mini thoracotomy (similar to a pacemaker implantation procedure or ICD implantation procedure) and advanced to the location where the thoracic duct 616 connects with the left subclavian or jugular veins 614, 620. The motor 618 that drives the pump 600 can be implanted in a subcutaneous pocket located below a shoulder bone, similar to pacemaker devices. Before the implantation of the pump 600, the thoracic duct 616 can be located using a guide wire insertion via the subclavian or jugular veins. Once inside, the pump 600 can be advanced to the venous angle, and the guide wire (not shown) can be manipulated until the thoracic duct 616 is found and entered. Once the thoracic duct 616 is found, the guide wire can be kept in place inside the thoracic duct, and the pump 600 can be advanced to the location where the inflow tube 602 is in the vein 614 with the inflow opening 604 thereof as close as possible to the thoracic duct 616. Once the pump 600 is activated (manually or automatically), blood can be sucked therein and advanced to the brachiocephalic vein. Around the inflow opening 604 of the pump 600 a low pressure zone will be created, thereby allowing for the lymphatic fluids to flow more easily and thus reduce the edema.
As illustrated, the restrictor 800 can include a balloon 802 configured to move between an activated configuration, shown in
The pumps described herein can be used in a variety of methods for treating pulmonary edema.
The method 500 can include creating 502 a subcutaneous pocket in a patient to contain an implantable pump therein. The subcutaneous pocket need not be created if the patient already has a location therein that can safely accommodate the pump. The pump can be implanted 504 in the patient, either in the created subcutaneous pocket or elsewhere.
The method 500 can include verifying 506 a location of the patient's thoracic duct and/or the patient's lymphatic duct, which can help a surgeon and/or other medical professional involved in performing a surgical procedure that includes implanting 504 the pump verify that the pump, an inflow tube coupled to the pump, and/or an outflow tube coupled to the pump are implanted in the correct location within the patient. If any one or more of the pump, the inflow tube, and the outflow tube is being implanted 504 in one of the patient's thoracic duct and/or the patient's lymphatic duct, the location at least that one of the thoracic duct and lymphatic duct can be verified 506 to help ensure that the pump, the inflow tube, and/or the outflow tube are implanted 504 at the desired location.
The verification 506 can be performed in any of a variety of ways, as will be appreciated by a person skilled in the art, such as by using an imaging technique such as echo or fluoroscopy. In an exemplary embodiment, the verification 506 can include advancing a set of pig tailed wires into the patient's subclavian or jugular veins and advanced toward a junction of the jugular and subclavian veins. Once one of the pig tailed wires enters the lymphatic duct or the thoracic duct, that one of the pig tailed wires can open itself inside the duct it entered, e.g., due to a default expanded configuration of the wire. The pig tailed wires can include, for example, a default expanded circle size of 4 cm. The location of the entered duct can be verified using an imaging technique that visualizes the expanded wire therein.
Although not shown in
With the pump implanted 504, the inflow and outflow tubes positioned 508, and, if being used in the system, the sensor implanted 510 and/or the fluid sack implanted, fluid flow can be controlled 512 with the pump. The control 512 can generally occur as described above. In at least some embodiments, controlling 512 the pump can include continuously running the pump. In at least some embodiments, controlling 512 the pump can include periodically running the pump.
One skilled in the art will appreciate further features and advantages of the invention based on the above-described embodiments. Accordingly, the invention is not to be limited by what has been particularly shown and described, except as indicated by the appended claims. All publications and references cited herein are expressly incorporated herein by reference in their entirety.
The present application is a continuation of U.S. nonprovisional application Ser. No. 14/726,715, filed Jun. 1, 2015, which claims priority to U.S. Provisional Patent Application No. 62/006,206 entitled “System And Method For Treatment of Pulmonary Edema” filed Jun. 1, 2014, the content of each of which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3211150 | Foderick | Oct 1965 | A |
3884240 | Gilman | May 1975 | A |
3926175 | Allen et al. | Dec 1975 | A |
4714460 | Calderon | Dec 1987 | A |
4822341 | CoIone | Apr 1989 | A |
4838864 | Peterson | Jun 1989 | A |
4957484 | Murtfeldt | Sep 1990 | A |
5005564 | Grundei et al. | Apr 1991 | A |
5069662 | Bodden | Dec 1991 | A |
5092844 | Schwartz et al. | Mar 1992 | A |
5097840 | Wallace et al. | Mar 1992 | A |
5366504 | Andersen et al. | Nov 1994 | A |
5391143 | Kensey | Feb 1995 | A |
5484412 | Pierpont | Jan 1996 | A |
5509897 | Twardowski et al. | Apr 1996 | A |
5554119 | Harrison et al. | Sep 1996 | A |
5558642 | Schweich, Jr. et al. | Sep 1996 | A |
5702364 | Euteneuer | Dec 1997 | A |
5716340 | Schweich, Jr. et al. | Feb 1998 | A |
5817046 | Glickman | Oct 1998 | A |
5836912 | Kusleika | Nov 1998 | A |
5893841 | Glickman | Apr 1999 | A |
5897533 | Glickman | Apr 1999 | A |
5908407 | Frazee et al. | Jun 1999 | A |
5919163 | Glickman | Jul 1999 | A |
5921913 | Siess | Jul 1999 | A |
6042569 | Finch, Jr. et al. | Mar 2000 | A |
6139517 | Macoviak et al. | Oct 2000 | A |
6152945 | Bachinski et al. | Nov 2000 | A |
6165196 | Stack et al. | Dec 2000 | A |
6179796 | Waldridge | Jan 2001 | B1 |
6183492 | Hart et al. | Feb 2001 | B1 |
6248091 | Voelker | Jun 2001 | B1 |
6254563 | Macoviak et al. | Jul 2001 | B1 |
6443884 | Miyawaki | Sep 2002 | B1 |
6503224 | Forman et al. | Jan 2003 | B1 |
6524323 | Nash et al. | Feb 2003 | B1 |
6555057 | Bendera | Apr 2003 | B1 |
6616623 | Kutushov | Sep 2003 | B1 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6699231 | Sterman et al. | Mar 2004 | B1 |
6878140 | Barbut | Apr 2005 | B2 |
6936057 | Nobles | Aug 2005 | B1 |
7022097 | Glickman | Apr 2006 | B2 |
7195608 | Burnett | Mar 2007 | B2 |
7645259 | Goldman | Jan 2010 | B2 |
7766892 | Keren et al. | Aug 2010 | B2 |
7780628 | Keren et al. | Aug 2010 | B1 |
8109880 | Pranevicius et al. | Feb 2012 | B1 |
8126538 | Shuros et al. | Feb 2012 | B2 |
8216122 | Kung | Jul 2012 | B2 |
8480555 | Kung | Jul 2013 | B2 |
8679057 | Fulton, III et al. | Mar 2014 | B2 |
9179921 | Morris | Nov 2015 | B1 |
9405942 | Liao et al. | Aug 2016 | B2 |
9421316 | Leeflang et al. | Aug 2016 | B2 |
9433713 | Corbett et al. | Sep 2016 | B2 |
9486566 | Siess | Nov 2016 | B2 |
9533054 | Yan et al. | Jan 2017 | B2 |
9533084 | Siess et al. | Jan 2017 | B2 |
9642991 | Eversull et al. | May 2017 | B2 |
9669142 | Spanier et al. | Jun 2017 | B2 |
9669144 | Spanier et al. | Jun 2017 | B2 |
9675739 | Tanner et al. | Jun 2017 | B2 |
9682223 | Callaghan et al. | Jun 2017 | B2 |
9750861 | Hastie et al. | Sep 2017 | B2 |
9770543 | Tanner et al. | Sep 2017 | B2 |
9878080 | Kaiser et al. | Jan 2018 | B2 |
9901722 | Nitzan et al. | Feb 2018 | B2 |
9962170 | Jansen et al. | May 2018 | B2 |
10149684 | Nitzan et al. | Dec 2018 | B2 |
10154846 | Nitzan et al. | Dec 2018 | B2 |
10195405 | Nitzan et al. | Feb 2019 | B2 |
10207086 | Nitzan et al. | Feb 2019 | B2 |
10226604 | Nitzan et al. | Mar 2019 | B2 |
10226605 | Nitzan et al. | Mar 2019 | B2 |
10245363 | Rowe | Apr 2019 | B1 |
10285708 | Nitzan et al. | May 2019 | B2 |
10300254 | Nitzan et al. | May 2019 | B2 |
10639460 | Nitzan et al. | May 2020 | B2 |
10653871 | Nitzan et al. | May 2020 | B2 |
10709878 | Nitzan et al. | Jul 2020 | B2 |
10912873 | Nitzan et al. | Feb 2021 | B2 |
10926069 | Nitzan et al. | Feb 2021 | B2 |
10960189 | Nitzan et al. | Mar 2021 | B2 |
11007353 | Gerrans et al. | May 2021 | B2 |
11166730 | Nitzan et al. | Nov 2021 | B2 |
11179550 | Nitzan et al. | Nov 2021 | B2 |
11179551 | Nitzan et al. | Nov 2021 | B2 |
11179552 | Nitzan et al. | Nov 2021 | B2 |
11357959 | Nitzan et al. | Jun 2022 | B2 |
11406393 | Nitzan | Aug 2022 | B2 |
20020010418 | Lary et al. | Jan 2002 | A1 |
20030093109 | Mauch | May 2003 | A1 |
20030134416 | Yamanishi et al. | Jul 2003 | A1 |
20030208097 | Aboul-Hosn et al. | Nov 2003 | A1 |
20040006306 | Evans et al. | Jan 2004 | A1 |
20040064091 | Keren et al. | Apr 2004 | A1 |
20040147871 | Burnett | Jul 2004 | A1 |
20040210296 | Schmitt et al. | Oct 2004 | A1 |
20040230181 | Cawood | Nov 2004 | A1 |
20050228474 | Laguna | Oct 2005 | A1 |
20050251180 | Burton et al. | Nov 2005 | A1 |
20060030814 | Valencia et al. | Feb 2006 | A1 |
20060064059 | Gelfand et al. | Mar 2006 | A1 |
20060100658 | Obana et al. | May 2006 | A1 |
20060161095 | Aboul-Hosn et al. | Jul 2006 | A1 |
20060178604 | Alderman | Aug 2006 | A1 |
20070055299 | Ishimaru et al. | Mar 2007 | A1 |
20070282303 | Nash et al. | Dec 2007 | A1 |
20070282382 | Shuros et al. | Dec 2007 | A1 |
20080009719 | Shuros et al. | Jan 2008 | A1 |
20080015628 | Dubrul et al. | Jan 2008 | A1 |
20080071135 | Shaknovich | Mar 2008 | A1 |
20080097412 | Shuros et al. | Apr 2008 | A1 |
20080103573 | Gerber | May 2008 | A1 |
20080140000 | Shuros et al. | Jun 2008 | A1 |
20080294228 | Brooke et al. | Nov 2008 | A1 |
20090018526 | Power et al. | Jan 2009 | A1 |
20090112184 | Fierens et al. | Apr 2009 | A1 |
20090131785 | Lee et al. | May 2009 | A1 |
20100168649 | Schwartz et al. | Jul 2010 | A1 |
20100179389 | Moroney, III et al. | Jul 2010 | A1 |
20100280451 | Teeslink et al. | Nov 2010 | A1 |
20100318114 | Pranevicius et al. | Dec 2010 | A1 |
20110004046 | Campbell et al. | Jan 2011 | A1 |
20110092955 | Purdy et al. | Apr 2011 | A1 |
20110257462 | Rodefeld et al. | Oct 2011 | A1 |
20110276023 | Leeflang et al. | Nov 2011 | A1 |
20110282274 | Fulton, III | Nov 2011 | A1 |
20110295302 | Mohl | Dec 2011 | A1 |
20120029466 | Callaghan et al. | Feb 2012 | A1 |
20120157913 | Aziz et al. | Jun 2012 | A1 |
20120178986 | Campbell et al. | Jul 2012 | A1 |
20120259215 | Gerrans et al. | Oct 2012 | A1 |
20130096476 | Rogachevsky | Apr 2013 | A1 |
20130096494 | Kassab | Apr 2013 | A1 |
20130138041 | Smisson, III et al. | May 2013 | A1 |
20130177432 | Toellner et al. | Jul 2013 | A1 |
20130237954 | Shuros et al. | Sep 2013 | A1 |
20130245607 | Eversull et al. | Sep 2013 | A1 |
20130303969 | Keenan et al. | Nov 2013 | A1 |
20130317535 | Demmy | Nov 2013 | A1 |
20130331814 | Fulton, III et al. | Dec 2013 | A1 |
20130338559 | Franano et al. | Dec 2013 | A1 |
20140010686 | Tanner et al. | Jan 2014 | A1 |
20140128659 | Heuring et al. | May 2014 | A1 |
20140142616 | Smith | May 2014 | A1 |
20140155815 | Fulton, III et al. | Jun 2014 | A1 |
20140220617 | Yung et al. | Aug 2014 | A1 |
20140243790 | Callaghan et al. | Aug 2014 | A1 |
20140249386 | Caron et al. | Sep 2014 | A1 |
20140296615 | Franano | Oct 2014 | A1 |
20140303461 | Callaghan et al. | Oct 2014 | A1 |
20140336551 | Mantese et al. | Nov 2014 | A1 |
20140358036 | Holmes | Dec 2014 | A1 |
20150051634 | Kravik et al. | Feb 2015 | A1 |
20150157777 | Tuval et al. | Jun 2015 | A1 |
20150164662 | Tuval | Jun 2015 | A1 |
20150238671 | Mesallum | Aug 2015 | A1 |
20150283360 | Kelly | Oct 2015 | A1 |
20150343136 | Nitzan et al. | Dec 2015 | A1 |
20150343186 | Nitzan et al. | Dec 2015 | A1 |
20160022890 | Schwammenthal et al. | Jan 2016 | A1 |
20160045203 | Pollock | Feb 2016 | A1 |
20160051741 | Schwammenthal et al. | Feb 2016 | A1 |
20160129266 | Schmidt | May 2016 | A1 |
20160166463 | Douglas et al. | Jun 2016 | A1 |
20160169630 | Augustine et al. | Jun 2016 | A1 |
20160213826 | Tanner et al. | Jul 2016 | A1 |
20160331378 | Nitzan et al. | Nov 2016 | A1 |
20170014563 | Khir | Jan 2017 | A1 |
20170095395 | Wennen et al. | Apr 2017 | A1 |
20170197021 | Nitzan et al. | Jul 2017 | A1 |
20170224512 | Hingston | Aug 2017 | A1 |
20170319764 | Tanner et al. | Nov 2017 | A1 |
20180012630 | Thomee et al. | Jan 2018 | A1 |
20180020456 | Wan et al. | Jan 2018 | A1 |
20180125499 | Nitzan et al. | May 2018 | A1 |
20180126130 | Nitzan et al. | May 2018 | A1 |
20180146968 | Nitzan et al. | May 2018 | A1 |
20180185622 | Nitzan et al. | Jul 2018 | A1 |
20180193614 | Nitzan et al. | Jul 2018 | A1 |
20180193615 | Nitzan et al. | Jul 2018 | A1 |
20180193616 | Nitzan et al. | Jul 2018 | A1 |
20180250456 | Nitzan et al. | Sep 2018 | A1 |
20180303986 | Meacham | Oct 2018 | A1 |
20190014991 | Maki et al. | Jan 2019 | A1 |
20190046706 | Aboul-Hosn et al. | Feb 2019 | A1 |
20190046707 | Aboul-Hosn et al. | Feb 2019 | A1 |
20190083761 | Nitzan et al. | Mar 2019 | A1 |
20190117943 | Nitzan et al. | Apr 2019 | A1 |
20190117944 | Nitzan et al. | Apr 2019 | A1 |
20190126014 | Kapur et al. | May 2019 | A1 |
20190167878 | Rowe | Jun 2019 | A1 |
20190223877 | Nitzan et al. | Jul 2019 | A1 |
20190366063 | Nitzan et al. | Dec 2019 | A1 |
20200016383 | Nitzan et al. | Jan 2020 | A1 |
20200030586 | Nitzan et al. | Jan 2020 | A1 |
20200030587 | Nitzan et al. | Jan 2020 | A1 |
20200046372 | Nitzan | Feb 2020 | A1 |
20200206485 | Nitzan et al. | Jul 2020 | A1 |
20200230380 | Nitzan et al. | Jul 2020 | A1 |
20200230381 | Nitzan et al. | Jul 2020 | A1 |
20200261706 | Nitzan et al. | Aug 2020 | A1 |
20200268951 | Nitzan et al. | Aug 2020 | A1 |
20200268952 | Nitzan et al. | Aug 2020 | A1 |
20200268954 | Nitzan et al. | Aug 2020 | A1 |
20200269025 | Nitzan et al. | Aug 2020 | A1 |
20200276369 | Nitzan et al. | Sep 2020 | A1 |
20200306436 | Tanner et al. | Oct 2020 | A1 |
20200397963 | Nitzan et al. | Dec 2020 | A1 |
20210121678 | Nitzan et al. | Apr 2021 | A1 |
20210378676 | Keating et al. | Dec 2021 | A1 |
20210378677 | Keating et al. | Dec 2021 | A1 |
20210378678 | Keating et al. | Dec 2021 | A1 |
20210379329 | Keating et al. | Dec 2021 | A1 |
20220039803 | Nitzan et al. | Feb 2022 | A1 |
20220104827 | Keating et al. | Apr 2022 | A1 |
20220104828 | Keating et al. | Apr 2022 | A1 |
20220218360 | Nitzan et al. | Jul 2022 | A1 |
20220218961 | Nitzan et al. | Jul 2022 | A1 |
20220280761 | Nitzan et al. | Sep 2022 | A1 |
20220280762 | Nitzan et al. | Sep 2022 | A1 |
20220331510 | Amstutz et al. | Oct 2022 | A1 |
Number | Date | Country |
---|---|---|
0526102 | Feb 1993 | EP |
2353501 | Aug 2011 | EP |
2353503 | Aug 2011 | EP |
2353632 | Aug 2011 | EP |
2497524 | Sep 2012 | EP |
2637927 | Sep 2013 | EP |
8904193 | May 1989 | WO |
2000024337 | May 2000 | WO |
01013983 | Mar 2001 | WO |
2012135834 | Oct 2012 | WO |
2013025826 | Feb 2013 | WO |
2013061281 | May 2013 | WO |
2014141284 | Sep 2014 | WO |
2015186003 | Dec 2015 | WO |
2017087556 | May 2017 | WO |
2018158636 | Sep 2018 | WO |
2018172848 | Sep 2018 | WO |
2018202776 | Nov 2018 | WO |
2019027380 | Feb 2019 | WO |
2020174285 | Sep 2020 | WO |
Entry |
---|
International Search Report and Written Opinion dated Oct. 30, 2018, for PCT/IB18/000364, filed Mar. 19, 2018 (9 pages). |
International Search Report and Written Opinion dated Jun. 25, 2018, for PCT/IB18/00263, filed Mar. 1, 2018 (10 pages). |
International Search Report and Written Opinion dated Apr. 12, 2018, for PCT/IB17/01488, filed Oct. 31, 2017 (11 pages). |
Non-Final Rejection issued in U.S. Appl. No. 16/867,047, dated Sep. 16, 2020, 11 pages. |
Non-Final Office Action issued in U.S. Appl. No. 15/799,562, dated Jul. 28, 2020 (8 pages). |
Non-Final Office Action issued in U.S. Appl. No. 15/870,111, dated Jun. 24, 2020 (5 pages). |
Bannon, 2011, Anatomic considerations for central venous cannulation, Risk Manag Healthc Policy 4:27-39. |
Moscucci, 2014, Section III Hemodynamic principles 10 Pressure measurement, 223-244 in Grossman & Bairn's Cardiac Catheterization, Angiography, and Intervention 8 Ed. |
Shimizu, 2014, Embolization of a fractured central venous catheter placed using the internal jugular apporach, Int J Surg Case Rep 5:219. |
Stone, 2010, The effect of rigid cervical collars on internal jugular vein dimensions, Acad Emerg Med 17(1): 100-102. |
Swan, 1970, Catheterization of the Heart in Man with Use of a Flow-directed Balloon-tipped Catheter, NEJM 283(9):447-451. |
Yancy, 2013, 2013 ACCF/AHA Guideline for the Management of Heart Failure, Circulation 128(16):e240-e327. |
Biran, 2017, Heparin coatings for improving blood compatibility of medical devices, Adv Drug Delivery Rev, 112:12-23. |
Webb, 2012, Roughness parameters for standard description of surface nanoarchitecture, Scanning 34:257-263. |
Blitz, 2014, Pump thrombosis—a riddle wrapped in a mystery inside an enigma, Ann Cardiothorac Surg, 3(5):450-471. |
Chikly, 2005, Manual techniques addressing the lymphatic system: origins and development, JAOA 105(10):457-464. |
Ratnayake, 2018, The Anatomy and physiology of the terminal thoracic duct and ostial valve in health and disease: potential implications for intervention, J Anat 233:1-14. |
Tchantchaleishvili, 2014, Evaluation and treatment of pump thrombosis and hemolysis, Ann Cardiothorac Surg, 3(5):490-495. |
Number | Date | Country | |
---|---|---|---|
20190083761 A1 | Mar 2019 | US |
Number | Date | Country | |
---|---|---|---|
62006206 | Jun 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14726715 | Jun 2015 | US |
Child | 16197667 | US |